Suchergebnisse - "Evans, Joanne S"

PubPharm (8)

1

SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer : results from the OnCovid registry

enthalten in: The Lancet. Oncology | 2023

von Cortellini, A. | Tabernero, J. | Mukherjee, U. | +126

2

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Pinato, D. | Ferrante, D. | Aguilar-Company, J. | +149

3

Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe : results from the retrospective, multicentre, OnCovid registry study

enthalten in: The Lancet. Oncology | 2022

von Pinato, D. | Aguilar-Company, J. | Ferrante, D. | +147

4

Time-Dependent COVID-19 Mortality in Patients With Cancer : An Updated Analysis of the OnCovid Registry

enthalten in: JAMA oncology | 2022

von OnCovid Study Group | Pinato, D. | Patel, M. | +78

5

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection : evidence from the OnCovid retrospective, multicentre registry study

enthalten in: The Lancet. Oncology | 2021

von Pinato, D. | Tabernero, J. | Bower, M. | +130

6

Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer : a European study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Pinato, D. | Scotti, L. | Gennari, A. | +67

CommentIn: Lancet Oncol. 2021 Jun;22(6):755. - PMID 33894836

7

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

enthalten in: Cancer discovery | 2020

von Pinato, D. | Zambelli, A. | Aguilar-Company, J. | +61

8

Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe

enthalten in: Cancers | 2020

von Pinato, D. | Lee, A. | Biello, F. | +37

1
[1]